$58.95
-0.90[-1.50%]
At close: May 10
$58.95
0[0.00%]
After Hours: 4:00PM EDT
Immunocore Hldgs
(NASDAQ:IMCR)Latest News for Immunocore Hldgs Stock (NASDAQ:IMCR)
Immunocore Hldgs Stock (NASDAQ: IMCR)
Categories: All
Thursday, May 09, 2024
- Canaccord Genuity Maintains Hold on Immunocore Hldgs, Raises Price Target to $67Benzinga Newsdesk - 3 days ago
- HC Wainwright & Co. Maintains Buy on Immunocore Hldgs, Raises Price Target to $100Benzinga Newsdesk - 3 days ago
- Needham Reiterates Buy on Immunocore Hldgs, Maintains $81 Price TargetBenzinga Newsdesk - 3 days ago
Monday, April 29, 2024
Tuesday, April 23, 2024
Thursday, April 11, 2024
Friday, April 05, 2024
Thursday, March 21, 2024
Wednesday, March 06, 2024
Tuesday, March 05, 2024
Thursday, February 29, 2024
- Key Takeaways From Immunocore Hldgs Analyst RatingsBenzinga Insights - Feb 29, 2024, 11:00AM
- Oppenheimer Reiterates Outperform on Immunocore Hldgs, Raises Price Target to $87Benzinga Newsdesk - Feb 29, 2024, 10:41AM
- Canaccord Genuity Maintains Hold on Immunocore Hldgs, Raises Price Target to $63Benzinga Newsdesk - Feb 29, 2024, 10:19AM
- Needham Reiterates Buy on Immunocore Hldgs, Maintains $81 Price TargetBenzinga Newsdesk - Feb 29, 2024, 5:07AM
Wednesday, February 28, 2024
Tuesday, February 27, 2024
Thursday, February 22, 2024
Friday, February 16, 2024
Thursday, February 01, 2024
Wednesday, January 31, 2024
Tuesday, January 30, 2024
Monday, January 29, 2024
- Immunocore Sees Increase In Q4 R&D Expenses And SG&A Expenses Vs Q3Benzinga Newsdesk - Jan 29, 2024, 5:15PM
- Immunocore Holdings Sees Prelim. Unaudited Cash And Cash Equivalents At Dec. 31 ~$443MBenzinga Newsdesk - Jan 29, 2024, 5:15PM
- Immunocore Holdings Expects Prelim. FY23 Unaudited Net Product Revenue ~235M Vs $249.08M Est.Benzinga Newsdesk - Jan 29, 2024, 5:13PM
- Immunocore Holdings Expects Prelim. Q4 2023 Unaudited Net Product Revenue ~$66M Vs $67.05M Est.Benzinga Newsdesk - Jan 29, 2024, 5:12PM
- Immunocore Announces Proposed Convertible Senior Notes Offering, Aggregate Amount $300MBenzinga Newsdesk - Jan 29, 2024, 4:43PM
Tuesday, January 16, 2024
Friday, January 05, 2024
- Immunocore's Pipeline Is Among The Strongest In Broader Biotech Universe: AnalystNabaparna Bhattacharya - Jan 5, 2024, 1:47PM
- Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day SessionAvi Kapoor - Jan 5, 2024, 1:13PM
- Immunocore Holdings shares are trading lower. The company announced strategic priorities and pipeline expansion.Benzinga Newsdesk - Jan 5, 2024, 11:16AM
- Immunocore Discloses Pipeline Expansion; Company Says It Is Advancing PRAME ImmTAC Including First Phase 3 Clinical Trial In Melanoma; Plans To Present Clinical Data From Phase 1/2 Clinical Trial In Melanoma, Ovarian, And Lung Cancer Throughout 2024Benzinga Newsdesk - Jan 5, 2024, 7:12AM
Monday, November 20, 2023
Tuesday, November 07, 2023
Thursday, November 02, 2023
Tuesday, October 31, 2023
Saturday, October 21, 2023
Thursday, October 05, 2023
Monday, October 02, 2023
Thursday, September 21, 2023
Wednesday, September 13, 2023
- Cancer Focused Immunocore Leads The Way In TCR Therapeutics, Positioned For Success: Analyst SaysVandana Singh - Sep 13, 2023, 2:32PM
- Analyst Expectations for Immunocore Hldgs's FutureBenzinga Insights - Sep 13, 2023, 11:01AM
- Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2023Benzinga Insights - Sep 13, 2023, 11:00AM
- Needham Initiates Coverage On Immunocore Hldgs with Buy Rating, Announces Price Target of $75Benzinga Newsdesk - Sep 13, 2023, 6:22AM